Timothy Yu, PhD, MD
Boston Children’s Hospital
Dr. Yu completed his undergraduate degree at Harvard College, his MD and PhD degrees from the University of California at San Francisco, neurology residency training at Massachusetts General Hospital and Brigham and Women’s Hospital, and neurogenetics fellowship at Massachusetts General Hospital and Boston Children’s Hospital. He joined the Boston Children’s Genetics and Genomics faculty as an instructor in 2010 and independent investigator in 2013. He is an Assistant Professor at Harvard Medical School. Dr. Yu also co-founded Claritas Genomics, a subsidiary of Boston Children’s, devoted to the practice of pediatric genomic medicine. His primary research focus is applying genetics and genomics to understanding the neurobiological bases of autism.
An MIT-trained mechanical engineer, Jamie entered the field of translational medicine when his 29 year old brother Stephen was diagnosed with ALS, or Lou Gehrig’s Disease. Described by CNNMoney as one of the 15 companies that will change the world, Jamie co-founded PatientsLikeMe to ensure patient outcomes become the primary driver of the medical care and discovery process. Jamie is also the founder and past CEO of the ALS Therapy Development Institute (ALS TDI), the world’s first non-profit biotechnology company. During his tenure at ALS TDI, Jamie helped pioneer an open research model and industrialized therapeutic validation process that made ALS TDI the world’s largest and most comprehensive ALS research program. Jamie has founded or co-founded three other health care companies: AOBiome, Genetic Networks, and TheSocialMedwork, and is an active member of a community of innovators working to bring dramatic improvements to the way we discover, develop and deliver effective health. Jamie and his brother were the subject of Pulitzer Prize-winning author Jonathan Weiner’s biography His Brother’s Keeper and the documentary So Much So Fast.
Jonathan J. Fleming is President and CEO of Q-State Biosciences, and early stage private funded neuroscience company in Cambridge MA. Q-State uses its proprietary technology platform to enable the discovery of new medicines for diseases such as ALS, epilepsy, Parkinson’s Disease and neuropathic pain. Prior to Q State Mr. Fleming was President of NEHI (Network for Excellence in Health Innovation) a nonprofit, non-partisan health policy institute focused on enabling innovations that improve the quality and lower the costs of health care. Since 1999, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, based in Boston, MA. Mr. Fleming has been in the investment business for more than 31 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in Seoul, Korea. He is also a director of Leerink Partners, a Boston based investment bank specializing in health care companies. In addition, Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a class on business strategy for life science managers. Mr. Fleming holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor’s degree in Political Science from the University of California, Berkeley.